| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Pneumonia, Ventilator-Associated | 17 | 2021 | 861 | 5.23 | Why? |
| Primary Graft Dysfunction | 4 | 2019 | 44 | 1.83 | Why? |
| Pseudomonas Infections | 4 | 2019 | 425 | 1.55 | Why? |
| Drug Resistance, Multiple, Bacterial | 6 | 2019 | 1115 | 1.47 | Why? |
| Anti-Bacterial Agents | 17 | 2020 | 10083 | 1.41 | Why? |
| Pneumonia, Bacterial | 8 | 2019 | 843 | 1.37 | Why? |
| Pseudomonas aeruginosa | 5 | 2019 | 652 | 1.30 | Why? |
| Intensive Care Units | 32 | 2020 | 29594 | 1.27 | Why? |
| Nebulizers and Vaporizers | 4 | 2018 | 497 | 1.26 | Why? |
| Acinetobacter Infections | 4 | 2019 | 273 | 1.04 | Why? |
| Lung Transplantation | 4 | 2019 | 1554 | 1.02 | Why? |
| Respiration, Artificial | 19 | 2021 | 22116 | 0.94 | Why? |
| Citrus sinensis | 1 | 2020 | 9 | 0.90 | Why? |
| Sepsis | 8 | 2018 | 3517 | 0.90 | Why? |
| Theranostic Nanomedicine | 2 | 2018 | 143 | 0.79 | Why? |
| Precision Medicine | 3 | 2018 | 1477 | 0.78 | Why? |
| Anti-Infective Agents | 4 | 2018 | 1766 | 0.73 | Why? |
| Colistin | 2 | 2017 | 217 | 0.72 | Why? |
| Pulmonary Atelectasis | 1 | 2018 | 80 | 0.71 | Why? |
| Community-Acquired Infections | 6 | 2020 | 2328 | 0.71 | Why? |
| Pseudomonas Vaccines | 1 | 2017 | 5 | 0.70 | Why? |
| Critical Illness | 13 | 2021 | 17281 | 0.69 | Why? |
| Security Measures | 1 | 2020 | 211 | 0.68 | Why? |
| Candidemia | 2 | 2018 | 353 | 0.65 | Why? |
| Hematologic Neoplasms | 3 | 2019 | 2105 | 0.64 | Why? |
| Acinetobacter baumannii | 4 | 2019 | 378 | 0.63 | Why? |
| Adrenomedullin | 1 | 2018 | 217 | 0.61 | Why? |
| Decision Support Systems, Clinical | 1 | 2020 | 551 | 0.57 | Why? |
| Phenotype | 3 | 2020 | 4037 | 0.56 | Why? |
| Steroids | 1 | 2020 | 904 | 0.56 | Why? |
| Pulmonary Edema | 1 | 2018 | 430 | 0.54 | Why? |
| Gram-Negative Bacterial Infections | 1 | 2019 | 398 | 0.53 | Why? |
| Skin | 3 | 2021 | 2096 | 0.53 | Why? |
| Respiratory Insufficiency | 7 | 2021 | 7301 | 0.51 | Why? |
| Influenza A Virus, H1N1 Subtype | 3 | 2019 | 2984 | 0.50 | Why? |
| Cross Infection | 12 | 2021 | 8675 | 0.49 | Why? |
| Oxygen | 4 | 2021 | 3715 | 0.48 | Why? |
| Critical Care | 9 | 2020 | 14081 | 0.48 | Why? |
| Brain Injuries, Traumatic | 1 | 2017 | 381 | 0.46 | Why? |
| Acute Lung Injury | 1 | 2020 | 904 | 0.45 | Why? |
| Ventilators, Mechanical | 3 | 2018 | 2193 | 0.45 | Why? |
| Emergency Treatment | 1 | 2018 | 719 | 0.45 | Why? |
| Noninvasive Ventilation | 3 | 2021 | 2329 | 0.44 | Why? |
| Legionnaires' Disease | 1 | 2012 | 108 | 0.43 | Why? |
| Congresses as Topic | 1 | 2020 | 1347 | 0.42 | Why? |
| SARS Virus | 3 | 2020 | 13021 | 0.40 | Why? |
| Influenza, Human | 6 | 2020 | 10779 | 0.40 | Why? |
| Bacterial Infections | 2 | 2019 | 2229 | 0.37 | Why? |
| Emergencies | 2 | 2021 | 4095 | 0.36 | Why? |
| Humans | 89 | 2021 | 930598 | 0.36 | Why? |
| Oxygen Inhalation Therapy | 3 | 2020 | 3629 | 0.35 | Why? |
| Refugees | 1 | 2017 | 809 | 0.33 | Why? |
| Microbial Sensitivity Tests | 5 | 2017 | 2886 | 0.33 | Why? |
| Disease Management | 3 | 2020 | 6841 | 0.32 | Why? |
| Invasive Pulmonary Aspergillosis | 3 | 2019 | 634 | 0.32 | Why? |
| Occupational Stress | 1 | 2020 | 2044 | 0.32 | Why? |
| Lung Diseases | 1 | 2019 | 2361 | 0.30 | Why? |
| Adrenal Cortex Hormones | 3 | 2020 | 6537 | 0.30 | Why? |
| Artificial Intelligence | 1 | 2020 | 3543 | 0.29 | Why? |
| Pneumonia | 3 | 2020 | 5652 | 0.29 | Why? |
| Nurses | 1 | 2020 | 2285 | 0.28 | Why? |
| APACHE | 2 | 2018 | 682 | 0.28 | Why? |
| Biomarkers | 8 | 2020 | 23361 | 0.27 | Why? |
| Gastrointestinal Hemorrhage | 2 | 2020 | 669 | 0.27 | Why? |
| Spain | 9 | 2020 | 15545 | 0.27 | Why? |
| Immunologic Factors | 1 | 2020 | 4206 | 0.27 | Why? |
| Physicians | 2 | 2020 | 4214 | 0.27 | Why? |
| Hypoxia | 4 | 2020 | 3626 | 0.26 | Why? |
| Skin Diseases | 1 | 2020 | 2509 | 0.26 | Why? |
| Prospective Studies | 14 | 2021 | 43301 | 0.25 | Why? |
| Severity of Illness Index | 9 | 2019 | 48226 | 0.24 | Why? |
| Antifungal Agents | 3 | 2018 | 1828 | 0.24 | Why? |
| Pulmonary Disease, Chronic Obstructive | 2 | 2019 | 3832 | 0.23 | Why? |
| Linear IgA Bullous Dermatosis | 1 | 2021 | 11 | 0.23 | Why? |
| Drug Resistance, Bacterial | 3 | 2019 | 1414 | 0.23 | Why? |
| Heel | 1 | 2020 | 19 | 0.22 | Why? |
| Male | 35 | 2021 | 367725 | 0.22 | Why? |
| Immunocompromised Host | 4 | 2019 | 5150 | 0.22 | Why? |
| Administration, Inhalation | 2 | 2018 | 1647 | 0.22 | Why? |
| Keratoderma, Palmoplantar | 1 | 2020 | 24 | 0.22 | Why? |
| Pneumonia, Pneumococcal | 1 | 2004 | 251 | 0.21 | Why? |
| Aerosols | 1 | 2017 | 5393 | 0.21 | Why? |
| Middle Aged | 30 | 2021 | 270681 | 0.21 | Why? |
| Systemic Vasculitis | 1 | 2021 | 74 | 0.21 | Why? |
| Respiratory Tract Infections | 2 | 2018 | 6817 | 0.20 | Why? |
| Skin Diseases, Vesiculobullous | 1 | 2021 | 112 | 0.20 | Why? |
| Hospital Mortality | 6 | 2021 | 22087 | 0.20 | Why? |
| Female | 32 | 2021 | 380317 | 0.20 | Why? |
| Lung Compliance | 1 | 2020 | 243 | 0.19 | Why? |
| Rome | 1 | 2020 | 497 | 0.18 | Why? |
| Consensus | 5 | 2020 | 6345 | 0.18 | Why? |
| Practice Guidelines as Topic | 4 | 2020 | 15421 | 0.18 | Why? |
| Bacterial Vaccines | 1 | 2019 | 139 | 0.18 | Why? |
| Piperacillin | 1 | 2017 | 63 | 0.17 | Why? |
| Contraindications, Procedure | 1 | 2018 | 161 | 0.17 | Why? |
| Aspergillus | 2 | 2017 | 347 | 0.17 | Why? |
| Pneumonia, Viral | 12 | 2020 | 243684 | 0.17 | Why? |
| Necrosis | 1 | 2020 | 532 | 0.17 | Why? |
| Amikacin | 1 | 2017 | 62 | 0.17 | Why? |
| Penicillanic Acid | 1 | 2017 | 58 | 0.17 | Why? |
| Hospitals, University | 3 | 2019 | 4173 | 0.17 | Why? |
| Complement System Proteins | 1 | 2021 | 380 | 0.17 | Why? |
| Tracheitis | 1 | 2017 | 43 | 0.16 | Why? |
| Public Health | 2 | 2021 | 16359 | 0.16 | Why? |
| Liposomes | 1 | 2019 | 334 | 0.16 | Why? |
| Syria | 1 | 2017 | 170 | 0.16 | Why? |
| Retrospective Studies | 12 | 2021 | 105322 | 0.16 | Why? |
| Proteoglycans | 1 | 2017 | 130 | 0.16 | Why? |
| Microbiological Techniques | 1 | 2019 | 232 | 0.16 | Why? |
| Organ Dysfunction Scores | 3 | 2018 | 1475 | 0.16 | Why? |
| Urea | 1 | 2017 | 228 | 0.16 | Why? |
| Bacteriophages | 1 | 2019 | 268 | 0.16 | Why? |
| Partial Pressure | 1 | 2017 | 279 | 0.16 | Why? |
| Cause of Death | 3 | 2019 | 4823 | 0.15 | Why? |
| Personal Protective Equipment | 1 | 2020 | 15978 | 0.15 | Why? |
| Bronchitis | 1 | 2017 | 146 | 0.15 | Why? |
| Risk Factors | 11 | 2021 | 71621 | 0.15 | Why? |
| Bacteremia | 2 | 2021 | 1372 | 0.15 | Why? |
| Prognosis | 6 | 2020 | 32490 | 0.15 | Why? |
| Bacteriological Techniques | 1 | 2017 | 239 | 0.15 | Why? |
| Enterobacteriaceae | 1 | 2019 | 395 | 0.15 | Why? |
| Calcitonin | 1 | 2017 | 201 | 0.15 | Why? |
| Immunotherapy | 2 | 2020 | 2421 | 0.15 | Why? |
| Invasive Fungal Infections | 1 | 2019 | 274 | 0.14 | Why? |
| Anxiety | 1 | 2020 | 17311 | 0.14 | Why? |
| Skin Diseases, Viral | 1 | 2021 | 436 | 0.14 | Why? |
| Pandemics | 12 | 2020 | 389249 | 0.14 | Why? |
| Organizational Policy | 1 | 2020 | 694 | 0.14 | Why? |
| Salvage Therapy | 1 | 2017 | 417 | 0.14 | Why? |
| Aged | 20 | 2021 | 215776 | 0.13 | Why? |
| Infectious Disease Medicine | 1 | 2017 | 311 | 0.13 | Why? |
| Pressure Ulcer | 1 | 2020 | 398 | 0.13 | Why? |
| Robotics | 1 | 2020 | 528 | 0.13 | Why? |
| Intubation, Intratracheal | 4 | 2017 | 3962 | 0.13 | Why? |
| Risk | 2 | 2019 | 5288 | 0.13 | Why? |
| Betacoronavirus | 8 | 2020 | 204454 | 0.13 | Why? |
| Placebos | 1 | 2017 | 629 | 0.13 | Why? |
| Review Literature as Topic | 1 | 2017 | 387 | 0.13 | Why? |
| Hospitals, Public | 1 | 2020 | 774 | 0.13 | Why? |
| Pulmonary Medicine | 1 | 2020 | 706 | 0.13 | Why? |
| Coronavirus Infections | 10 | 2020 | 253789 | 0.13 | Why? |
| Drug Utilization | 1 | 2019 | 619 | 0.13 | Why? |
| Infection Control | 3 | 2018 | 23131 | 0.13 | Why? |
| Survival Rate | 3 | 2018 | 9206 | 0.13 | Why? |
| Health Care Surveys | 2 | 2020 | 2942 | 0.13 | Why? |
| Terminology as Topic | 1 | 2019 | 546 | 0.13 | Why? |
| Stem Cells | 1 | 2019 | 595 | 0.13 | Why? |
| Klebsiella pneumoniae | 1 | 2019 | 658 | 0.13 | Why? |
| Administration, Intranasal | 1 | 2018 | 1132 | 0.13 | Why? |
| Advisory Committees | 1 | 2020 | 1418 | 0.12 | Why? |
| AIDS-Related Opportunistic Infections | 1 | 1995 | 260 | 0.12 | Why? |
| Adult | 16 | 2021 | 244371 | 0.12 | Why? |
| Data Accuracy | 1 | 2018 | 715 | 0.12 | Why? |
| Metabolomics | 1 | 2018 | 921 | 0.12 | Why? |
| Bronchoalveolar Lavage Fluid | 2 | 2019 | 2309 | 0.12 | Why? |
| Cannula | 1 | 2018 | 750 | 0.12 | Why? |
| Drug Prescriptions | 1 | 2020 | 1062 | 0.12 | Why? |
| Neoplasm Proteins | 1 | 2017 | 501 | 0.12 | Why? |
| Interleukins | 1 | 2017 | 762 | 0.11 | Why? |
| Public Health Practice | 1 | 2020 | 945 | 0.11 | Why? |
| Urinary Tract Infections | 1 | 2017 | 534 | 0.11 | Why? |
| Heart | 1 | 2021 | 1791 | 0.11 | Why? |
| Bronchoscopy | 1 | 2019 | 991 | 0.11 | Why? |
| Observational Studies as Topic | 1 | 2019 | 1887 | 0.11 | Why? |
| Pneumonia, Pneumocystis | 1 | 1995 | 322 | 0.11 | Why? |
| Antimicrobial Stewardship | 1 | 2019 | 931 | 0.11 | Why? |
| Coronavirus | 1 | 2020 | 18339 | 0.10 | Why? |
| Fatal Outcome | 1 | 2020 | 3438 | 0.10 | Why? |
| Shock, Septic | 2 | 2018 | 1313 | 0.10 | Why? |
| Intensive Care Units, Pediatric | 1 | 2017 | 1098 | 0.10 | Why? |
| Hydrocortisone | 1 | 2020 | 1790 | 0.10 | Why? |
| Drug Administration Schedule | 1 | 2017 | 2324 | 0.10 | Why? |
| Meta-Analysis as Topic | 1 | 2017 | 1289 | 0.10 | Why? |
| Patient Readmission | 1 | 2019 | 1543 | 0.10 | Why? |
| Randomized Controlled Trials as Topic | 2 | 2020 | 10649 | 0.10 | Why? |
| Neoplasms | 1 | 2018 | 17251 | 0.10 | Why? |
| Postoperative Complications | 2 | 2019 | 5861 | 0.10 | Why? |
| Endothelium, Vascular | 1 | 2021 | 1751 | 0.10 | Why? |
| Multivariate Analysis | 2 | 2017 | 5440 | 0.10 | Why? |
| Extracorporeal Membrane Oxygenation | 2 | 2019 | 5002 | 0.10 | Why? |
| Health Surveys | 1 | 2020 | 2841 | 0.10 | Why? |
| Dexamethasone | 1 | 2020 | 2055 | 0.10 | Why? |
| Length of Stay | 4 | 2020 | 11042 | 0.09 | Why? |
| Acute Disease | 2 | 2019 | 6029 | 0.09 | Why? |
| Odds Ratio | 2 | 2017 | 5861 | 0.09 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2012 | 12361 | 0.09 | Why? |
| Physical Therapy Modalities | 1 | 2017 | 1090 | 0.09 | Why? |
| Europe | 4 | 2020 | 12702 | 0.09 | Why? |
| Videoconferencing | 1 | 2020 | 2081 | 0.09 | Why? |
| Microbiota | 1 | 2018 | 1240 | 0.09 | Why? |
| Internationality | 1 | 2020 | 3297 | 0.08 | Why? |
| Thromboembolism | 1 | 2020 | 2101 | 0.08 | Why? |
| Autopsy | 1 | 2019 | 3495 | 0.08 | Why? |
| Delayed Diagnosis | 1 | 2017 | 1529 | 0.08 | Why? |
| Follow-Up Studies | 3 | 2021 | 17020 | 0.08 | Why? |
| Recovery of Function | 1 | 2017 | 2461 | 0.08 | Why? |
| International Cooperation | 1 | 2020 | 3436 | 0.08 | Why? |
| Seasons | 1 | 2019 | 4071 | 0.08 | Why? |
| Patient Positioning | 1 | 2017 | 1505 | 0.08 | Why? |
| Symptom Assessment | 1 | 2020 | 4967 | 0.08 | Why? |
| Kidney Diseases | 1 | 2017 | 1434 | 0.08 | Why? |
| Echinocandins | 2 | 2017 | 139 | 0.08 | Why? |
| Turkey | 1 | 2017 | 3937 | 0.08 | Why? |
| Adolescent | 5 | 2021 | 86841 | 0.08 | Why? |
| Sex Factors | 2 | 2020 | 11014 | 0.08 | Why? |
| Kidney | 1 | 2020 | 3648 | 0.08 | Why? |
| Poverty | 1 | 2018 | 2302 | 0.08 | Why? |
| Inflammation Mediators | 1 | 2017 | 2654 | 0.07 | Why? |
| Time Factors | 4 | 2018 | 31397 | 0.07 | Why? |
| Prone Position | 1 | 2017 | 1861 | 0.07 | Why? |
| Double-Blind Method | 1 | 2017 | 5988 | 0.07 | Why? |
| Health Care Rationing | 1 | 2020 | 2558 | 0.07 | Why? |
| Liver Cirrhosis | 1 | 2017 | 1810 | 0.07 | Why? |
| Logistic Models | 4 | 2019 | 9089 | 0.07 | Why? |
| Interleukin-6 | 2 | 2020 | 7522 | 0.07 | Why? |
| Age Factors | 3 | 2021 | 21039 | 0.07 | Why? |
| Prevalence | 2 | 2017 | 25773 | 0.07 | Why? |
| Guidelines as Topic | 1 | 2017 | 2844 | 0.07 | Why? |
| Immunization, Passive | 1 | 2020 | 10067 | 0.07 | Why? |
| Observation | 1 | 2004 | 80 | 0.07 | Why? |
| Aged, 80 and over | 6 | 2020 | 88759 | 0.07 | Why? |
| Societies, Medical | 1 | 2020 | 6907 | 0.07 | Why? |
| Machine Learning | 1 | 2020 | 4395 | 0.07 | Why? |
| Hospitalization | 4 | 2020 | 54280 | 0.07 | Why? |
| Gastrointestinal Microbiome | 1 | 2017 | 1961 | 0.07 | Why? |
| Diagnosis, Differential | 1 | 2018 | 7220 | 0.06 | Why? |
| Algorithms | 2 | 2017 | 7346 | 0.06 | Why? |
| Patient Discharge | 1 | 2019 | 5696 | 0.06 | Why? |
| Global Health | 2 | 2020 | 13911 | 0.06 | Why? |
| Survival Analysis | 1 | 2017 | 7592 | 0.06 | Why? |
| Case-Control Studies | 2 | 2017 | 17671 | 0.06 | Why? |
| Young Adult | 3 | 2019 | 93724 | 0.06 | Why? |
| Drug Therapy, Combination | 2 | 2017 | 7268 | 0.06 | Why? |
| Predictive Value of Tests | 1 | 2017 | 9537 | 0.06 | Why? |
| Treatment Outcome | 5 | 2019 | 51732 | 0.06 | Why? |
| Venous Thromboembolism | 1 | 2020 | 4273 | 0.06 | Why? |
| Databases, Factual | 1 | 2017 | 6248 | 0.06 | Why? |
| Virus Internalization | 1 | 2020 | 7921 | 0.06 | Why? |
| Glucocorticoids | 1 | 2017 | 4431 | 0.06 | Why? |
| Health Behavior | 1 | 2020 | 4449 | 0.06 | Why? |
| Lung | 3 | 2020 | 31049 | 0.06 | Why? |
| Specimen Handling | 1 | 2019 | 6190 | 0.05 | Why? |
| Triage | 1 | 2020 | 7151 | 0.05 | Why? |
| Pulmonary Embolism | 1 | 2020 | 4775 | 0.05 | Why? |
| Incidence | 3 | 2021 | 25622 | 0.05 | Why? |
| Antibodies, Monoclonal | 1 | 2019 | 8041 | 0.05 | Why? |
| Biomedical Research | 1 | 2020 | 5270 | 0.05 | Why? |
| Perfusion | 1 | 2020 | 254 | 0.05 | Why? |
| Lithuania | 1 | 2019 | 92 | 0.05 | Why? |
| Combined Modality Therapy | 2 | 2020 | 3395 | 0.05 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 9335 | 0.05 | Why? |
| Drug Resistance, Multiple | 1 | 1999 | 156 | 0.05 | Why? |
| Clinical Trials as Topic | 1 | 2018 | 7330 | 0.05 | Why? |
| Cytokines | 2 | 2017 | 15010 | 0.04 | Why? |
| Ghana | 1 | 2021 | 763 | 0.04 | Why? |
| Acinetobacter | 1 | 1997 | 58 | 0.04 | Why? |
| Treatment Failure | 1 | 2004 | 2106 | 0.04 | Why? |
| Risk Assessment | 2 | 2019 | 25439 | 0.04 | Why? |
| Bacterial Load | 1 | 2017 | 179 | 0.04 | Why? |
| Stress, Mechanical | 1 | 2017 | 143 | 0.04 | Why? |
| Glasgow Coma Scale | 1 | 2018 | 249 | 0.04 | Why? |
| Travel | 1 | 2016 | 7220 | 0.04 | Why? |
| Norway | 1 | 2021 | 1004 | 0.04 | Why? |
| Russia | 1 | 2021 | 989 | 0.04 | Why? |
| Hand | 1 | 2021 | 449 | 0.04 | Why? |
| Cohort Studies | 2 | 2019 | 36005 | 0.04 | Why? |
| Fungal Proteins | 1 | 2017 | 133 | 0.04 | Why? |
| Intraabdominal Infections | 1 | 2017 | 90 | 0.04 | Why? |
| Arterial Pressure | 1 | 2018 | 208 | 0.04 | Why? |
| Colombia | 1 | 2021 | 1241 | 0.04 | Why? |
| Amphotericin B | 1 | 2017 | 256 | 0.04 | Why? |
| Surveys and Questionnaires | 2 | 2020 | 43792 | 0.04 | Why? |
| Suction | 1 | 1997 | 297 | 0.04 | Why? |
| Voriconazole | 1 | 2017 | 206 | 0.04 | Why? |
| Carbapenems | 1 | 2019 | 343 | 0.04 | Why? |
| Emergency Service, Hospital | 1 | 2020 | 14232 | 0.04 | Why? |
| Vaccination | 1 | 2021 | 19050 | 0.04 | Why? |
| Craniocerebral Trauma | 1 | 1997 | 160 | 0.04 | Why? |
| Paris | 1 | 1999 | 1287 | 0.04 | Why? |
| Erythrocyte Transfusion | 1 | 2019 | 386 | 0.04 | Why? |
| Confidence Intervals | 1 | 1997 | 744 | 0.04 | Why? |
| Infant | 1 | 2017 | 30274 | 0.03 | Why? |
| United States | 2 | 2020 | 46150 | 0.03 | Why? |
| ROC Curve | 2 | 2019 | 6024 | 0.03 | Why? |
| Child, Preschool | 1 | 2017 | 36283 | 0.03 | Why? |
| Data Interpretation, Statistical | 1 | 2017 | 657 | 0.03 | Why? |
| China | 1 | 2020 | 50654 | 0.03 | Why? |
| Candida | 1 | 2017 | 425 | 0.03 | Why? |
| Off-Label Use | 1 | 2017 | 553 | 0.03 | Why? |
| Health Services Research | 1 | 2018 | 756 | 0.03 | Why? |
| South Africa | 1 | 2021 | 3326 | 0.03 | Why? |
| Kaplan-Meier Estimate | 1 | 2020 | 4260 | 0.03 | Why? |
| Computed Tomography Angiography | 1 | 2020 | 2153 | 0.03 | Why? |
| Animals | 1 | 2019 | 78931 | 0.02 | Why? |
| Comorbidity | 3 | 2020 | 34796 | 0.02 | Why? |
| Sputum | 1 | 1997 | 1720 | 0.02 | Why? |
| Antiviral Agents | 2 | 2020 | 41703 | 0.02 | Why? |
| Argentina | 1 | 2012 | 1141 | 0.02 | Why? |
| Dose-Response Relationship, Drug | 1 | 2017 | 3776 | 0.02 | Why? |
| Drug Combinations | 1 | 2017 | 3852 | 0.02 | Why? |
| Biofilms | 1 | 2009 | 304 | 0.02 | Why? |
| Enteral Nutrition | 1 | 2009 | 320 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2021 | 9893 | 0.02 | Why? |
| Terminal Care | 1 | 1995 | 928 | 0.02 | Why? |
| Costs and Cost Analysis | 1 | 2009 | 694 | 0.02 | Why? |
| Ventilator Weaning | 1 | 2009 | 536 | 0.02 | Why? |
| Respiratory System | 1 | 2017 | 3213 | 0.02 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 5993 | 0.02 | Why? |
| Catheterization, Central Venous | 1 | 1989 | 458 | 0.02 | Why? |
| Clinical Decision-Making | 1 | 2017 | 3755 | 0.02 | Why? |
| Developing Countries | 1 | 2018 | 4283 | 0.01 | Why? |
| Multicenter Studies as Topic | 1 | 2009 | 2437 | 0.01 | Why? |
| Patient Acceptance of Health Care | 1 | 2020 | 5002 | 0.01 | Why? |
| Coinfection | 1 | 2021 | 6820 | 0.01 | Why? |
| Reproducibility of Results | 1 | 2017 | 11304 | 0.01 | Why? |
| Equipment Contamination | 1 | 2009 | 1308 | 0.01 | Why? |
| Radiography, Thoracic | 1 | 2017 | 5486 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2021 | 11041 | 0.01 | Why? |
| United Kingdom | 1 | 2021 | 18046 | 0.01 | Why? |
| Cross-Sectional Studies | 2 | 2018 | 53120 | 0.01 | Why? |
| Practice Patterns, Physicians' | 1 | 2019 | 4927 | 0.01 | Why? |
| Brain | 1 | 1997 | 5133 | 0.01 | Why? |
| Disease Outbreaks | 2 | 2020 | 27595 | 0.01 | Why? |
| Hand Disinfection | 1 | 2009 | 1671 | 0.01 | Why? |
| Hospitals | 1 | 2019 | 11793 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2018 | 22971 | 0.01 | Why? |
| Italy | 1 | 2021 | 38444 | 0.01 | Why? |
| Inflammation | 1 | 2017 | 13255 | 0.01 | Why? |
| Renal Dialysis | 1 | 1989 | 4358 | 0.01 | Why? |
| Child | 1 | 2018 | 70012 | 0.01 | Why? |